▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for PainReform in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.49.
The current consensus among 1 investment analysts is to buy stock in PainReform.
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of products for the treatment of pain in Israel. It develops PRF-110, a product based on local anesthetic ropivacaine, which completed Phase II clinical study in hernia repair. The company was founded in 2007 and is headquartered in Herzeliya, Israel.